TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth by Takeuchi, Kyoko et al.
TGF-b Inhibition Restores Terminal Osteoblast
Differentiation to Suppress Myeloma Growth
Kyoko Takeuchi
1, Masahiro Abe
1*, Masahiro Hiasa
2, Asuka Oda
1, Hiroe Amou
1, Shinsuke Kido
1, Takeshi
Harada
1, Osamu Tanaka
1, Hirokazu Miki
1, Shingen Nakamura
1, Ayako Nakano
1, Kumiko Kagawa
1,
Kenichiro Yata
1, Shuji Ozaki
3, Toshio Matsumoto
1
1Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima, Japan, 2Department of Biomaterials and
Bioengineering, University of Tokushima Graduate School of Oral Sciences, Tokushima, Japan, 3Division of Transfusion Medicine, Tokushima University Hospital,
Tokushima, Japan
Abstract
Background: Multiple myeloma (MM) expands almost exclusively in the bone marrow and generates devastating bone
lesions, in which bone formation is impaired and osteoclastic bone resorption is enhanced. TGF-b, a potent inhibitor of
terminal osteoblast (OB) differentiation, is abundantly deposited in the bone matrix, and released and activated by the
enhanced bone resorption in MM. The present study was therefore undertaken to clarify the role of TGF-b and its inhibition
in bone formation and tumor growth in MM.
Methodology/Principal Findings: TGF-b suppressed OB differentiation from bone marrow stromal cells and MC3T3-E1
preosteoblastic cells, and also inhibited adipogenesis from C3H10T1/2 immature mesenchymal cells, suggesting
differentiation arrest by TGF-b. Inhibitors for a TGF-b type I receptor kinase, SB431542 and Ki26894, potently enhanced
OB differentiation from bone marrow stromal cells as well as MC3T3-E1 cells. The TGF-b inhibition was able to restore OB
differentiation suppressed by MM cell conditioned medium as well as bone marrow plasma from MM patients. Interestingly,
TGF-b inhibition expedited OB differentiation in parallel with suppression of MM cell growth. The anti-MM activity was
elaborated exclusively by terminally differentiated OBs, which potentiated the cytotoxic effects of melphalan and
dexamethasone on MM cells. Furthermore, TGF-b inhibition was able to suppress MM cell growth within the bone marrow
while preventing bone destruction in MM-bearing animal models.
Conclusions/Significance: The present study demonstrates that TGF-b inhibition releases stromal cells from their
differentiation arrest by MM and facilitates the formation of terminally differentiated OBs, and that terminally differentiated
OBs inhibit MM cell growth and survival and enhance the susceptibility of MM cells to anti-MM agents to overcome the drug
resistance mediated by stromal cells. Therefore, TGF-b appears to be an important therapeutic target in MM bone lesions.
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Introduction
Multiple myeloma (MM) develops and expands almost exclusively
in the bone marrow and generates devastating bone lesions. In
typical destructive bone lesions in patients with MM, bone
formation is impaired along with an enhancement of osteoclastic
bone resorption. We and others have demonstrated that MM cells
enhance osteoclastogenesis by MIP-1 and RANK ligand,[1,2,3,4]
while suppressing osteoblast (OB) differentiation from their
precursors, stromal cells, via the secretion of soluble Wnt antagonists
from MM cells,[5,6,7] stromal cells and OBs.[8,9] Thus induced
osteoclasts (OCs) as well as stromal cells with defective OB
differentiation in turn enhance MM cell growth and survival.[10,11]
Furthermore, OCs stimulate angiogenesis in concert with MM
cells.[12] These MM cell-induced cell types in MM bone lesions,
namely OCs, vascular endothelial cells and stromal cells, create a
microenvironment suitable for MM cell growth and survival, which
can be called as a ‘‘MM niche’’. [13] Because such a skewed cellular
microenvironment protects MM cells from apoptosis induced by
chemotherapeutic agents as well as immunotherapy, there is a need
to target and disrupt the MM niche to improve the efficacy of
present therapeutic modalities against MM progression as well as
MM bone disease.
Bone marrow stromal cells with defective OB differentiation are
a major component of the MM niche, which produce various
growth and anti-apoptotic factors for MM cells including IL-6,
IGF-1, SDF-1a and VEGF while expressing RANK ligand to
stimulate osteoclastogenesis. Importantly, the adhesion of MM
cells to stromal cells as well as their extracellular matrices (ECM)
confers cell adhesion-mediated drug resistance (CAM-DR) in MM
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OB differentiation in stromal cells not only prevents bone loss and
resumes bone formation in MM bone lesions, but also may perturb
MM growth enhanced by stromal cells.
TGF-b, a potent inhibitor of terminal OB differentiation and
mineralization,[17,18,19] is produced by OBs and osteocytes, and
abundantly deposited in bone matrices in a latent form.[20] It is
released from bone matrices through bone resorption[21] and
activated by acids and matrix metalloproteinases secreted from
OCs.[22,23,24] Because osteoclastic bone resorption is enhanced
in MM, TGF-b appears to be abundant and active in MM bone
lesions, and may play an important role in bone formation
impaired by MM. Therefore, the present study was undertaken to
explore whether an inhibition of TGF-b enhances OB differen-
tiation suppressed by MM, and whether an enhancement of OB
differentiation affects MM cell growth and survival. We demon-
strate herein that a blockade of TGF-b actions releases stromal
cells from their differentiation arrest by MM, and that terminally
differentiated OBs inhibit MM cell growth and survival and
potentiate responsiveness to anti-MM agents. These results suggest
that suppression of OB differentiation by MM not only accelerates
bone loss but also creates a MM niche to enhance MM growth
Figure 1. TGF-b suppresses and TGF-b inhibitors enhance OB differentiation. MC3T3-E1 cells (A) and primary bone marrow stromal cells (B)
were cultured for 14 and 28 days, respectively, in 24-well culture plates in a-MEM containing 10% FBS supplemented with b-glycerophosphate and
ascorbic acid (osteogenic medium). rhBMP-2, SB431542, Ki26894 and rhTGF-b were added at 50 ng/mL, 3 mM, 10 mM and 5 ng/mL to the indicated
wells, respectively. After culturing, mineralized nodules were visualized by von Kossa staining. C. MC3T3-E1 cells were cultured for 21 days in
osteogenic media in the absence of BMP-2. SB431542 was added at 3 mM to the indicated wells. Mineralized nodules were visualized by von Kossa
staining. The data with mineralized nodule formation were quantified by densitometric analyses.
doi:10.1371/journal.pone.0009870.g001
Figure 2. TGF-b suppresses adipogenic differentiation as well as OB differentiation from immature mesenchymal cells. A. C3H10T1/2
immature mesenchymal cells were cultured in osteogenic medium for 7 days. rhBMP-2, SB431542 and rhTGF-b were added at 50 ng/mL, 3 mM and
5 ng/mL to the indicated wells, respectively. After culturing for 7days, the cells were stained with oil red O. Representative images of oil red O
staining are shown. B. C3H10T1/2 cells were harvested after culturing for 2 days. rhBMP-2, SB431542 and rhTGF-b were added at 50 ng/mL, 3 mM and
5 ng/mL to the indicated wells, respectively. mRNA expression of markers for adipogenic and osteoblastic differentation were analyzed by RT-PCR.
The primers used were as follows: Mouse adioponectin sense 59-AGGGTGAGACAGGAGATGTTGGAA-39 and antisense 59-CAGAGGCCTGGTCCA-
CATTCTTTT-39. Mouse aP2 sense 59-TCTCACCTGGAAGACAGCTCCTCCTCG-39 and antisense 59-TTCCATCCAGGCCTCTTCCTTTGGCTC-39. Mouse ALP
sense 59-CACTCAGGGCAATGAGGTCACATC-39 and antisense 59-TTCAGTGCGGTTCCAGACATAGTG-39.
doi:10.1371/journal.pone.0009870.g002
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TGF-b inhibition may provide a novel approach to ameliorate
both bone destruction and tumor progression in MM.
Results
TGF-b suppresses and TGF-b inhibitors enhance OB
differentiation
Because OB differentiation from stromal cells is impaired in
MM bone lesions, and because TGF-b is activated through
enhanced bone resorption, we first examined the effect of TGF-b
and its inhibition on OB differentiation. Addition of BMP-2
induced OB differentiation with the formation of mineralized
nodules by MC3T3-E1 preosteoblastic cells (Figure 1A) and
primary bone marrow stromal cells from a patient with MM
(Figure 1B). Interestingly, treatment with inhibitors of the TGF-b
type I receptor kinase ALK5, SB431542 and Ki26894, to inhibit
endogenous TGF-b increased the formation of mineralized
nodules. To simulate TGF-b-rich MM bone lesions, we added
TGF-b, and examined OB differentiation in the presence of TGF-
b. Addition of TGF-b almost completely suppressed the BMP-2-
induced formation of mineralized nodules. However, treatment
with SB431542 or Ki26894 restored the mineralization on
addition of TGF-b. In addition, SB431542 alone facilitated
osteogenesis to achieve mineralized nodule formation by
MC3T3-E1 cells even in the absence of BMP-2 (Figure 1C),
which may be due to the suppression of endogenous TGF-b
produced by MC3T3-E1 cells. Thus, TGF-b suppresses and its
inhibition enhances OB differentiation.
TGF-b suppresses adipogenic differentiation as well as
OB differentiation from immature mesenchymal cells
In addition to OB differentiation, BMP-2 can induce the
differentiation of mesenchymal stem cells or pluripotent
C3H10T1/2 immature mesenchymal cells into adipocytes .[25,26]
When C3H10T1/2 cells were cultured in an osteogenic medium
with BMP-2, significant numbers of oil red O-positive adipocytes
appeared (Figure 2A). Addition of SB431542 to suppress endoge-
nous TGF-b actions enhanced adipogenic differentiation by BMP-2.
TGF-b almost completely suppressed adipogenic differentiation,
which resumed with the addition of SB431542. Also, the mRNA
expression of adipogenic differentiation markers including adiopo-
nectin and aP2 was induced along with the expression of ALP, a
marker for OBs, by BMP-2, which was further up-regulated by
TGF-b inhibition (Figure 2B). TGF-b suppressed the expression of
both the adipogenic and OB differentiation markers, which was
reversed by TGF-b inhibition. Thus, TGF-b suppresses adipogenic
as well as osteoblastic differentiation in C3H10T1/2 cells, suggesting
immaturity of undifferentiated mesenchymal cells or stromal cells
retained by TGF-b.
TGF-b inhibition restores and enhances OB
differentiation suppressed by MM
Because MM cells produce soluble Wnt antagonists and
suppress OB differentiation,[5,6,7] we next examined whether
TGF-b inhibition can restore OB differentiation suppressed by
MM cells. Conditioned media from MM cell lines suppressed the
development of mineralized nodules stimulated by BMP-2
(Figure 3A). Addition of SB431542 or Ki26894 restored the
modulation in the presence of MM cell conditioned media to a
level more than BMP-2 alone, suggesting that TGF-b inhibition
antagonizes the suppression of OB differentiation by MM cells. To
further investigate the effects of TGF-b inhibition on OB
differentiation in the context of the MM bone marrow microen-
vironment, we looked at the effect of TGF-b inhibition on the
formation of mineralized nodules in the presence of bone marrow
plasma collected from three MM patients with extensive bone
destruction. Bone marrow plasma from all these MM patients
suppressed the development of mineralized nodules (Figure 3B).
Treatment with SB431542 restored and enhanced the minerali-
zation suppressed by the bone marrow plasma from MM patients.
These results suggest that the inhibition of TGF-b restores OB
differentiation and bone formation suppressed in MM.
Because TGF-b inhibition antagonizes the suppressive effects of
MM cell conditioned media on OB differentiation (Figure 3A), we
next examined whether TGF-b inhibition influences canonical
Wnt signaling suppressed by MM cells, using luciferase reporter
assays of the T-cell factor (TCF)/ lymphoid enhancer factor (LEF)
transcription factor, a downstream target of a canonical Wnt
signaling pathway. Addition of MM cell conditioned media
suppressed the TCF/LEF reporter activity in MC3T3-E1 cells
(Figure 3C). The TCF/LEF reporter activity remained suppressed
after the addition of SB431542 at doses high enough to restore OB
differentiation, suggesting that TGF-b inhibition does not affect
canonical Wnt signaling down-regulated by MM cells.
To further investigate mechanisms of stimulation of mineralized
nodule formation by TGF-b inhibition, we next looked at the
effect of SB431542 on BMP-2 signaling. Binding of BMP-2 to its
cognate receptors enhances phosphorylation of Smad1, a
downstream effecter of a canonical BMP-2 signaling pathway.
Indeed, addition of BMP-2 induced phosphorylation of Smad1
(Figure 3D). Interestingly, pretreatment with SB431542 further
potentiated the phosphorylation of Smad1 by BMP-2. Pretreat-
ment with TGF-b inhibited the phosphorylation of Smad1 by
BMP-2; however, addition of SB431542 together with TGF-b
restored the BMP-2-induced phosphorylation of Smad1.
SB431542 abolished the phosphorylation of Smad2 by TGF-b
in MC3T3-E1 cells (Figure 3D), which confirmed the specific
inhibition of TGF-beta signaling by SB431542. These results are
consistent with the notion that TGF-b inhibition potentiates BMP-
2 action and releases OB precursor cells from the blockade of
Figure 3. TGF-b inhibition restores OB differentiation and potentiates Smad1 phosphorylation by BMP-2. A. MC3T3-E1 cells were
cultured for 14 days in osteogenic media in the absence or presence of conditioned media from RPMI8226 and U266 cells at 20%. SB431542 and
Ki26894 were added at 3 and 10 mM to the indicated wells, respectively. B. MC3T3-E1 cells were cultured for 14 days in osteogenic media in the
absence or presence of bone marrow plasma from patients with MM at 5%. SB431542 was added at 3 mM to the indicated wells. C. A chimeric firefly
luciferase reporter plasmid (Topflash) and a renilla luciferase reporter plasmid (pRL-TK) were cotransfected into MC3T3-E1 cells as described in
Materials and methods. The MC3T3-E1 cells were cultured in osteogenic media with rhBMP-2 at 50 ng/ml in the absence or presence of conditioned
medium from RPMI8226 cells at 10%. SB431542 was added at 3 mM to the indicated wells. After 12 hours of incubation luiferase reporter activity was
measured as renilla luiferase activity. Data were expressed as means +/2 SD for six independent experiments. D. MC3T3-E1 cells were cultured in a-
MEM with 1% FBS for 24 hours in 10-cm dishes at 60% confluence. SB431542 (3 mM), rhTGF-b (10 ng/mL), and the two in combination were added to
the indicated dishes and the cells were cultured for another 48 hours, after which rhBMP-2 was added at 200 ng/ml (upper). SB431542 (3 mM), rhTGF-
b (10 ng/mL), and the two in combination were added to the indicated dishes (lower). Following incubation for 30 minutes, cell lysates were
collected. The protein levels of phosphorylated Smad1, Smad1, phosphorylated Smad2 and Smad2 were estimated by Western blotting. b-actin was
used as a protein loading control.
doi:10.1371/journal.pone.0009870.g003
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9870Figure 4. Terminally differentiated OBs suppress MM cell growth. A. MC3T3-E1 cells and primary bone marrow stromal cells isolated from a
patient with MM were cultured in 24-well culture plates in a-MEM containing 10% FBS with or without b-glycerophosphate, ascorbic acid and 50 ng/
mL rhBMP-2 as described in ‘‘Materials and methods’’. After forming mineralized nodules in the osteogenic cultures with rhBMP-2, the cells were
washed to remove rhBMP-2. MM cell lines, 5TGM1, RPMI8226, U266 and KMS-12 at 5610
4/mL, were cultured alone as a control or cocultured in
quadruplicate with thus treated MC3T3-E1 cells or primary bone marrow stromal cells with or without inducing terminal OB differentiation. After
culturing for 3 days, MM cells were harvested, and viable MM cell numbers were counted. Percent changes from the control are shown. Results are
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signaling down-regulated by MM cells.
Terminally differentiated OBs suppress MM cell growth
and survival
To determine whether induction of OB differentiation in
stromal cells affects the MM cell growth-promoting activity of
stromal cells, we examined MM cell growth and survival in
cocultures with MC3T3-E1 cells or bone marrow stromal cells
isolated from a patient with MM with or without induction of
terminal OB differentiation. Terminally differentiated OBs
forming mineralized nodules derived from MC3T3-E1 cells or
primary stromal cells markedly reduced the viability of MM cell
lines, while untreated MC3T3-E1 cells or primary stromal cells
without OB differentiation did not (Figure 4A). We next
determined whether or not the suppression of growth and survival
by terminally differentiated OBs is specific to MM cells. CD138-
positive MM cells and CD138-negative non-MM cells were
immunomagnetically isolated from bone marrow aspirates from
MM patients, and cocultured with untreated or terminally
differentiated MC3T3-E1 cells. The viability of CD138-positive
primary MM cells was substantially decreased after coculturing
with MC3T3-E1 cells with mineralized nodules, while CD138-
negative normal hematopoietic cells remained intact (Figure 4B).
MC3T3-E1 cells without OB differentiation showed suppressive
effects on neither CD138-positive nor negative cells. Thus,
terminally differentiated OBs suppress the growth and survival
of MM cells but not normal hematopoietic cells in the bone
marrow.
Terminally differentiated OBs induce MM cell apoptosis
with G1 arrest
We next investigated the effects of terminally differentiated
MC3T3-E1 cells on the induction of apoptosis and cell cycle
distribution of MM cells. Viable 5TGM1 MM cells slightly
increased in number when cocultured with untreated MC3T3-E1
cells (Figure 5A, middle). However, a large number of 5TGM1
MM cells underwent apoptosis with positive staining of annexin V
when cocultured with differentiated MC3T3-E1 cells with
mineralized nodules (Figure 5A, right). Untreated MC3T3-E1
cells increased the number of 5TGM1 cells in S phase (Figure 5B,
middle). In contrast, 5TGM1 cells in S phase almost completely
disappeared, and those in G0/G1 and sub-G0/G1 substantially
increased in number when cocultured with MC3T3-E1 cells with
mineralized nodules (Figure 5B, right). These results demonstrate
that terminally differentiated OBs induce MM cell apoptosis with
G1 arrest.
Because stromal cells with suppressed OB differentiation in MM
confer drug resistance in MM cells, we next determined whether
the induction of terminal OB differentiation can reverse the
protective effects of stromal cells on MM cell viability against anti-
MM chemotherapeutic agents, melphalan and dexamethasone.
Untreated MC3T3-E1 cells attenuated the cytotoxic effects of
melphalan (Figure 5C left) and dexamethasone (Figure 5C right)
on RPMI8226 MM cells. In contrast, differentiated MC3T3-E1
cells with mineralized nodules did not show protective effects on
MM cells and further enhanced the cytotoxicity of these agents
against MM cells. These results demonstrate that the induction of
terminal OB differentiation can abolish the stromal cell-induced
resistance against anti-MM agents, and that the susceptibility of
MM cells to anti-MM agents can be reinforced by enhancing the
terminal differentiation of OBs.
Enhancement of OB maturation by TGF-b inhibition
facilitates the suppression of MM cell growth
To determine whether TGF-b can expedite OB differentiation,
we next sequentially analyzed the effects of inhibiting TGF-b on
the formation of mineralized nodules by MC3T3-E1 preosteo-
blastic cells. SB431542 facilitated OB differentiation as evidenced
by the enhanced development of mineralized nodules at day 6,
earlier than that with BMP-2 alone (Figure 6A). Addition of TGF-
b almost completely suppressed the BMP-2-induced formation of
mineralized nodules even at day 12. However, with SB431542 the
modulation resumed as early as day 6 even in the presence of
TGF-b. These results demonstrate that TGF-b inhibition
expedites OB maturation even in a TGF-b-rich milieu.
We next determined whether enhancement of OB maturation
by TGF-b inhibition can suppress MM cell growth at earlier time
points. After MC3T3-E1 cells had achieved different stages of OB
differentiation through culturing with or without BMP-2 and/or
SB431542 for 3, 6 and 9 days, they were washed and subsequently
cocultured with 5TGM1 MM cells for 3 days. ALP activity in
MC3T3-E1 cells was already enhanced at day 3 in the presence of
BMP-2 (Figure 6B, upper panels), while no mineralized nodules
were observed (Figure 6B, middle panels). Despite the elevation of
ALP activity at day 3, 5TGM1 MM cell growth was not
suppressed when the MM cells were cocultured with MC3T3-E1
cells at this stage of differentiation (Figure 6B, lower panels). In
contrast, suppression of MM cell growth was observed in parallel
with the development of mineralized nodules by cocultured
MC3T3-E1 cells after 6 and 9 days in the presence of BMP-2
with or without SB431542, and correlated well with the levels of
mineralization. These results suggest that terminally differentiated
mature OBs with mineralized nodules have the ability to suppress
MM cell growth and survival, and that TGF-b inhibition can
expedite the differentiation of OBs to suppress MM cell growth
and survival.
TGF-b inhibition suppresses MM cell growth and
formation of bone destructive lesions in MM-bearing
SCID-rab mice
To evaluate in vivo the effects of TGF-b inhibition on both MM
cell growth and the formation of bone destructive lesions, we first
established MM-bearing animal models developing a bone disease.
Because most MM cell lines grow rapidly and disseminate
extraosseously in SCID mice, we utilized an IL-6 or stromal
cell-dependent human MM cell line, INA6, which has been shown
to hardly grow subcutaneously but grow within a human fetal
bone implanted in SCID mice (SCID-hu mice).[27] SCID-rab
mice have been developed to substitute for SCID-hu mice to
recapitulate MM expansion within the bone marrow and
formation of a bone disease.[28] Therefore, we generated SCID-
rab MM models using INA6 cells. INA6 cells were inoculated
directly into the bone marrow cavity in rabbit bones implanted
expressed as means +/2 SD. *, ,0.05. B. CD138-positive MM cells and CD138-negative non-MM bone marrow cells were immunomagnetically
isolated from bone marrow aspirates of MM patients. The cells were cultured alone or co-cultured in triplicate with MC3T3-E1 cells with or without
mineralization. After culturing for 3 days, the MM and non-MM bone marrow cells were harvested and viable cell numbers were counted. Data were
expressed as means +/2 SD. *, p,0.05.
doi:10.1371/journal.pone.0009870.g004
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9870Figure 5. Terminally differentiated OBs induce MM cell apoptosis with G1 arrest. A. 5TGM1 cells (5610
4/mL) were cultured alone or co-
cultured with MC3T3-E1 cells with or without mineralized nodules. After culturing for 2 days, 5TGM1 cells were collected, stained with FITC-labeled
annexin V and PI, and analyzed by flow cytometry. B. 5TGM1 cells were cultured alone, or cocultured with MC3T3-E1 cells with or without mineralized
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IL-6 receptor was detected as a marker for MM tumor growth 4
weeks after the inoculation of INA6 cells in all the SCID-rab mice,
which demonstrates that the rabbit bone microenvironment allows
the growth of INA6 cells. Because sera from mice orally treated
with the TGF-b type I receptor kinase inhibitor Ki26894
effectively inhibited most of TGF-beta-induced reporter activi-
ty,[29] we treated INA6-bearing SCID-rab mice with an oral
administration of Ki26894 according to procedures described
before.[29] We analyzed MM cell growth and the formation of
bone lesions in vehicle- or Ki26894-treated mice 6 weeks after the
inoculation of INA6 cells. In vehicle-treated mice, the levels of
human soluble IL-6 receptor,[27] a marker for human myeloma
tumor burden, in mouse sera were substantially increased
(Figure 7A); radiolucent osteolytic lesions were observed in the
implanted rabbit bones (Figure 7B). In histological analyses, MM
cells were tightly packed in the bone marrow cavity of the rabbit
bones while bone trabeculae decreased in size (Figure 7C).
However, in Ki26894-treated mice, serum levels of soluble IL-6
receptor remained low (Figure 7A) and only marginal bone
destruction was observed on X-ray radiography (Figure 7B). The
MM cells markedly decreased in number and formed only small
foci in rabbit bones, while bone trabeculae remained without
apparent loss of size and structure, and cuboid cells lined the
surface of bone, namely osteoblasts (Figure 7C). For quantitative
histomorphometric analyses, we measured bone volume per tissue
volume (BV/TV) and osteoblast surface per bone surface (Ob.S/
BS) of rabbit bones in MM-bearing SCID-rab mice as the indices
of bone destruction and osteoblast function, respectively. Both
BV/TV and Ob.S/BS were markedly suppressed in vehicle-
treated mice. However, both indices retained significantly higher
in Ki26894-treated mice, suggesting the protection of bone in vivo
by TGF-b inhibition. We also measured tumor per tissue volume
(tumor/TV) to assess a tumor burden of the rabbit bones in MM-
bearing SCID-rab mice. Tumor/TV was markedly reduced in
Ki26894-treated mice (Figure 7D), which is consistent with the
serum levels of soluble human IL-6R, a surrogate marker for a
human MM tumor burden, in MM-bearing SCID-rab mice.
These results suggested that TGF-b inhibition can suppress MM
cell growth within the bone marrow while preventing bone
destruction and loss.
Discussion
BMP[30,31] and canonical Wnt pathways[32,33] are among
the predominant signaling pathways stimulating OB differentia-
tion. A canonical Wnt pathway in OBs is suppressed by soluble
Wnt antagonists elaborated by MM cells,[5,6,7] stromal cells and
OBs.[8,9] The present study demonstrated that TGF-b plays an
important role in arresting the differentiation of stromal cells into
mature OBs and that TGF-b suppresses BMP-2 signaling
(Figure 3D). In osteolytic lesions in MM which enhance the
release and activation of TGF-b, a BMP as well as canonical Wnt
signaling pathway in stromal cells and OBs appears to be
suppressed, causing severe suppression of OB differentiation.
Interestingly, a blockade of TGF-b antagonized the suppressive
effects of MM cell conditioned media (Figure 3A) and bone
marrow plasma from MM patients (Figure 3B), and was able to
release stromal cells from differentiation arrest to achieve terminal
OB differentiation. Although the mechanism whereby TGF-b
inhibits OB differentiation still remains unclear, we found at least
in our experimental conditions that TGF-b inhibition markedly
enhances the phosphorylation of Smad1 to potentiate BMP-2
signaling without affecting the canonical Wnt pathway in OB
precursor cells suppressed by MM cells (Figures 3C-D). Therefore,
the potentiation of BMP-2 signaling at least in part contributes to
the restoration of OB differentiation caused by the inhibition of
TGF-b.
In the present study, TGF-b inhibition was shown to facilitate
terminal OB differentiation in parallel with suppression of MM
cell growth and survival. A reverse correlation between OB
differentiation and MM tumor growth has recently been reported
in patients with MM treated with the proteasome inhibitor
bortezomib. Serum levels of bone-specific ALP were found to be
elevated after treatment with bortezomib, which were inversely
correlated with a reduction in tumor burden.[34,35,36] Such bone
anabolic effects of bortezomib and their correlation with tumor
regression were further demonstrated in MM animal models.[37]
MM growth inhibition associated with OB differentiation was also
observed in MM animal models treated with other anabolic agents
such as anti-DKK1 antibody[38] and lithium chloride[39] as well
as with enforced expression of Wnt3a within bone.[40] Together
with our results with TGF-b inhibitors, these observations suggest
that anti-MM activity emerges with OB differentiation, and that
MM cells may protect themselves from such OB-mediated growth
suppression by inhibiting the terminal differentiation of OBs.
We found that treatment with the TGF-b type I receptor kinase
inhibitor Ki26894 in MM-bearing SCID-rab mice suppressed
MM cell growth within the bone marrow while preventing bone
destruction and loss (Figure 7). In vivo effects of TGF-b inhibition
have also been studied with the TGF-b type I receptor kinase
inhibitor SD-208, and shown to increase bone mass in mammary
tumor-bearing mice (Mohammad KS, Stebbins E, Kingsley L, et
al. J Bone Miner Metab. 2008;23 abstract F275) as well as normal
mice.[41] Pharmacological blockade of TGF-b action by the anti-
TGF-b monoclonal antibody 1D11 has also been demonstrated to
reduce serum M-protein levels as well as improve bone volume
and strength in 5TGM1-bearing mouse MM models (Hart AJ,
Fowler JA, Lwin ST, et al. J Bone Miner Metab. 2008;23 abstract
F293). Together with these in vivo results, our study demonstrates
that TGF-b appears to be an important therapeutic target in MM
bone lesions. However, because TGF-b inhibitors including
SB431542 and Ki26894 did not show direct cytotoxic effects on
MM cells (Figure 7E), the combination of TGF-b inhibitors with
cytoreductive chemotherapeutic agents or bortezomib may further
improve the therapeutic efficacy against MM.
Stromal cells together with OCs create a MM niche in the bone
marrow to promote MM cell growth and protect MM cells from
spontaneous and drug-induced apoptosis. Stromal cells confer
potent drug resistance to blunt the efficacy of anti-MM
agents.[14,15,16] Importantly, terminally differentiated OBs
potentiate cytotoxic effects of melphalan and dexamethasone
(Figure 5C), suggesting that mature OBs can increase the
susceptibility of MM cells to anti-MM agents to overcome the
drug resistance mediated by stromal cells. These results are
consistent with a hypothesis that induction of OB differentiation
nodules for 2 days. 5TGM1 cells were analyzed by flow cytometry with dual staining of BrdU and 7-AAD as described in ‘‘Materials and methods’’.
Cells were gated corresponding to cell cycle distribution. C. RPMI8226 cells were cultured alone or cocultured with MC3T3-E1 cells with or without
mineralization in quadruplicate for 3 days in the absence or presence of melphalan at 20 mM (left) or dexamethasone at 10 mM (right). Viable
RPMI8226 cells were counted.
doi:10.1371/journal.pone.0009870.g005
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9870can not only ameliorate destructive bone lesions, but also disrupt
the MM niche to suppress MM growth. Furthermore, TGF-b is a
multi-functional cytokine which suppresses normal hematopoie-
sis[42] and dendritic cell differentiation[43] but enhances
angiogenesis[44] as well as osteoclastogenesis.[45] Therefore, the
effect of TGF-b inhibition may extend beyond amelioration of
destructive bone lesions and tumor growth and improve other
MM-associated clinical features.
It is intriguing that OBs which have matured enough to form
mineralized nodules suppress the proliferation of MM cells in
sharp contrast to their precursor, stromal cells, which support MM
cell growth and survival. The production of IL-6, a major stromal
cell-derived growth and anti-apoptotic factor for MM cells, was
found to be markedly decreased in terminally differentiated OBs
(91.265.7 and 15.162.7 pg/mL for 2 days in culture supernatants
of untreated and terminally differentiated MC3T3-E1 cells,
respectively). Recently, decorin has been identified among OB-
derived factors responsible for the suppression of MM cell growth
and survival. [46]Profiles of protein production during OB
differentiation by a proteome analysis may help identify the OB
signature responsible for MM growth suppression.
Materials and Methods
Ethics Statement
All procedures involving human specimens were performed
under written informed consent according to the Declaration of
Helsinki and the protocol approved by the Institutional Review
Board for human protection in University of Tokushima (#240).
All experiments with animals were performed according to the
guidelines for animal protection in University of Tokushima, and
approved by the Institutional Review Board for animal protection.
Reagents
TGF-b type I receptor kinase activin-like kinase 5 (ALK5)
inhibitors, SB431542 and Ki26894, were obtained as follows.
SB431542 was purchased from Tocris Bioscience (Ellisville,
MO). Its IC50 for ALK5 is 94 nM.[47] Ki26894 was a gift from
Kyowa Hakko Kirin Co. Ltd. (Japan), and is suitable for
experiments in vivo.[29] The following reagents were purchased
from the indicated manufacturers: recombinant human (rh)
bone morphogenetic protein (BMP)-2 and rhTGF-b from R&D
Systems (Minneapolis, MN); b-glycerophosphate, melphalan,
dexamethasone, rh biglycan, rh decorin and rabbit anti-b-actin
polyclonal antibody from Sigma (St. Louis, MO); ascorbic acid
from Wako Pure Chemical (Osaka, Japan); rh soluble RANK
ligand from Pepro Tech (Rocky Hill, NJ); rabbit anti-Smad1
and rabbit anti-Smad2 from Millipore (Billerica, MA); and
anti-phosphorylated Smad1, anti-phosphorylated Smad2 and
horseradish peroxidase–conjugated anti-mouse IgG from Cell
Signaling (Beverly, MA).
Cells and cultures
Human MM cell lines, RPMI8226 and U266, were obtained
from the American Type Culture Collection (Rockville, MD).
The human MM cell line KMS-12 was obtained from Health
Science Research Resources Bank (Osaka, Japan). The MM
cell line INA6 was kindly provided by Dr. Renate Burger
(University of Kiel, Kiel, Germany). The mouse MM cell line
5TGM1 was a gift from Dr. Gregory R. Mundy (Vanderbilt
Center for Bone Biology, Vanderbilt University, Nashville, TN).
A mouse preosteoblastic cell line, MC3T3-E1, and an immature
mesenchymal cell line, C3H10T1/2 were obtained from
RIKEN Bioresource Center (Tsukuba, Japan). Human bone
marrow mononuclear cells were isolated by Ficoll-Hypaque
density gradient centrifusion from heparinized bone marrow
blood drawn from patients with MM. MM cells were further
purified from bone marrow mononuclear cells with positive
selection using CD138 (Syndecan-1) microbeads and the
Miltenyi magnetic cell-sorting system (Miltenyi Biotec, Auburn,
CA) according to instructions. Primary stromal cells were
isolated from bone marrow aspirate sa n dc u l t u r e da sp r e v i o u s l y
described.[5] Cells were cultured in Minimal Essential Medium
Eagle-Alpha Modification (a-MEM; Sigma) with 10% heat-
inactivated fetal bovine serum (FBS; SAFC Biosciences, Lenexa,
KS) or 1% FBS as a serum-reduced condition, 100 units/mL
penicillin(Sigma) and 100 mg/mL streptomycin (Sigma). Con-
ditioned media were collected from MM cell lines cultured at
5610
5 cells/mL for 2 days. Bone marrow plasma was obtained
after the centrifusion of heparinized bone marrow blood drawn
from patients with MM.
OB differentiation
MC3T3-E1 pre-osteoblastic cells and bone marrow-derived
stromal cells were cultured in 24-well culture plates in an
osteogenic medium, a-MEM containing 10% FBS, 10 mM b-
glycerophosphate and 50 mg/mL ascorbic acid, as previously
described.[5] The medium was replaced every 3 days. Alkaline
phosphatase (ALP) activity was determined using an ALP
activity assay kit (Wako Pure Chemical) according to the
manufacturer’s instructions. For analyzing mineralized nodules,
the cells were fixed with 10% neutral-buffered formalin (Wako
Pure Chemical) and visualized by von Kossa staining as
described.[5]
Adipogenic differentation
C3H10T1/2 cells were cultured in an osteogenic medium with
BMP-2. On day 7 of adipogenic induction, cells were washed,
fixed and stained for intracellular lipid inclusion bodies with 0.5%
oil red O (Sigma) in isopropanol:distilled water (60:40) for 30
minutes.
RT-PCR
Total RNA was extracted from cells using TRIZOL reagent
(Gibco BRL, Rockville, MD). For reverse transcription-polymer-
ase chain reaction (RT-PCR), 2 mg of total RNA was reverse-
transcribed with Superscript II (Gibco) in a 20-ml reaction solution.
One tenth of the RT-PCR product was used for subsequent PCR
analysis with 24–30 cycles of 95uC for 30 seconds, 58uC for 30
seconds, and 72uC for 30 seconds.
Figure 6. TGF-b inhibition facilitates terminal OB maturation to suppress MM growth and survival at earlier time points. A. MC3T3-E1
cells were cultured in osteogenic media for the indicated periods. rhBMP-2, SB431542 and rhTGF-b were added at 50 ng/mL, 3 mM and 5 ng/mL to
the indicated wells, respectively. After culturing, mineralized nodules were visualized by von Kossa staining. B. MC3T3-E1 cells were cultured in
osteogenic media for induction of OB differentiation. rhBMP-2 and SB431542 were added at 50 ng/mL and 3 mM to the indicated wells, respectively.
After culturing for 3, 6 and 9 days, the cells were washed, and subjected to the measurement of ALP activity (top panels) and von Kossa staining for
assessing mineralized nodule formation (middle panels). The cells were also cocultured in quadruplicate with 5TGM1 cells for 3 days. Viable 5TGM1
cells were counted. Percent changes from the baseline are shown (bottom panels). Data are expressed as means +/2 SD. *, p,0.05.
doi:10.1371/journal.pone.0009870.g006
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MC3T3-E1 cells were seeded in 6-well culture plates at 50%
confluence and co-transfected with 2 mg of chimeric firefly
luciferase reporter plasmid with Renilla luciferase reporter plasmid
(pRL-TK; Promega, Madison, WI) as an internal control using
GenePorter2 transfection reagent (Genlantis Inc., San Diego, CA)
in opti-MEM (Invitrogen, Carlsbad, CA) supplemented with 1%
FBS. A TCF/LEF binding site reporter plasmid was used
(Topflash
TM; Upstate Biotechnology, Lake Placid, NY). The
medium was replaced with aMEM containing 1% FBS at 16
hours after transfection. For dual-luciferase assays, the cells were
washed and lysed with a passive cell lysis buffer (Promega,
Madison, WI), and both firefly and renilla luciferase activity was
measured with a luminometer (ATTO, Tokyo, Japan) by mixing
the luciferase substrate (Promega) with 10 mL of cell lysate.
Transcriptional activity was expressed as renilla luciferase activity.
Western blot analysis
Cells were collected and lysed in a lysis buffer (Cell Signaling)
supplemented with 1 mM phenylmethylsulfonyl fluoride and
protease inhibitor cocktail solution (Sigma). Cell lysates were
separated by SDS-PAGE and transferred to polyvinylidene
difluoride membranes (Millipore). Membranes were blocked with
5% non-fat dry milk in TBS with 0.01% Tween 20 (MP
Biomedicals, Irvine, CA) for one hour at room temperature and
incubated for 16 hours at 4uC with anti-phospholylated-Smad1,
anti-Smad1, or anti-b-actin antibody. After washing, secondary
horseradish peroxidase–conjugated antibody was added, and the
membranes were developed using the Enhanced Chemilumines-
cence Plus Western Blotting Detection System (Amersham
Biosciences, Piscataway, NJ).
Cell viability and cell cycle analysis
Viable cell numbers were measured by a cell proliferation assay
using 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium (WST-8; Kishida Chemical, Osaka,
Japan), or a trypan blue exclusion assay, as previously
described.[12] Apoptosis was evaluated by staining cells with an
annexin V-FITC and propidium iodide (PI) labeling kit (MEB-
CYTO Apoptosis Kit; MBL,Nagano, Japan) according to
instructions. Cell cycle distribution was evaluated by staining cells
with a bromodeoxyuridine (BrdU) and 7-amino-actinomycin D (7-
AAD) labeling kit (BrdU Flow Kit; BD Pharmingen, San Diego,
CA) according to instructions. Briefly, cells were cultured with
BrdU at 10 mM for the last 2 hours of culture. They were
collected, fixed, and incubated with a FITC-conjugated monoclo-
nal antibody against BrdU. 7-AAD (20 mL per sample) was added
for DNA staining. BrdU incorporation and DNA content were
analyzed by flow cytometry.
MM mouse model and measurement of serum soluble
human IL-6 receptor levels
The SCID-rab MM mouse model was prepared as de-
scribed.[28] Briefly, femora and tibiae from 4-week-old Japanese
white rabbits (Kitayama Labes, Nagano, Japan) were implanted
subcutaneously into six-week-old male CB-17 SCID mice (CLEA
Japan, Tokyo, Japan). After allowing bone engraftment for 4 weeks
following the implantation, 1610
6 INA-6 cells in 50 mLo f
phosphate-buffered saline (PBS) was inoculated directly into the
bone marrow cavity of the rabbit bones. A TGF-beta type I
receptor kinase inhibitor, Ki26894, was mixed with food (0.08%)
and administered orally via chow as previously reported.[29] The
treatment with Ki26894 was initiated 1 day after the inoculation of
INA6 cells. Serum levels of soluble human IL-6 receptor derived
from INA6 cells were used as a marker for tumor burden as
previously described.[27] Mouse sera were serially collected and
serum levels of soluble human IL-6 receptor were measured with an
enzyme-linked immunosorbent assay (human IL-6 sR; R&D
Systems, Minneapolis, MN). Six weeks after the MM cell
inoculation, the mice were anesthetized with an i.p. injection of
pentobarbital (Dainippon Pharma, Osaka, Japan). X-ray photo-
graphs of the rabbit bones were taken, and the rabbit bones were
collected. The rabbit bones were fixed in 10% phosphate-buffered
formalin, and decalcified with 10% EDTA. The samples were
further embedded in paraffin, and sectioned. Sections were stained
with hematoxylin and eosin (H&E) for histopathologic examination.
Bone volume per tissue volume (BV/TV), osteoblast surface per
bone surface (Ob.S/BS) and tumor per tissue volume (tumor/TV)
were measured in decalcified implanted rabbit bone sections stained
with H&E as the indices of bone destruction, osteoblast function
and a tumor burden, respectively, as described previously. [48,49]
Quantification of data
Raw image data of mineralized nodule formation and
immunobolotting were quantified with the Multi Gauge version
3.0 software (Fujifilm, Tokyo, Japan).
Statistical analysis
Statistical significance was determined by a one-way analysis of
variance (ANOVA) with Scheffe post hoc tests. The minimal level
of significance was a p value equal to 0.05.
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